The semaglutide dosing schedule is a structured titration from a subtherapeutic starting dose to a maintenance target, spread over two to four months. It is designed this way because semaglutide’s gastrointestinal side effects are dose-dependent, and a gradual increase is the single most effective tool for reducing nausea, vomiting, and treatment discontinuation. The specific schedule depends on which product is prescribed — Ozempic, Wegovy, or Rybelsus.
Why Semaglutide Is Titrated
Semaglutide activates GLP-1 receptors throughout the body, including in the gut, where it slows gastric emptying and sends satiety signals to the brain. Those mechanisms are responsible for most of the drug’s glucose-lowering and appetite-suppressing effect, but they also explain why a sudden therapeutic dose often triggers intense nausea. Starting low and stepping up every four weeks gives the gastrointestinal tract time to adapt. The schedule is a general framework, not a prescriptive recommendation — your clinician tailors it to your tolerance, goals, and comorbidities.
Ozempic (Injectable Semaglutide for Type 2 Diabetes)
Ozempic is FDA-approved to improve glycemic control in adults with type 2 diabetes and to reduce the risk of major cardiovascular events in adults with type 2 diabetes and established cardiovascular disease. The FDA prescribing information outlines the following schedule:
- Weeks 1–4: 0.25 mg once weekly (initiation only, not for glycemic effect)
- Weeks 5–8: 0.5 mg once weekly (first therapeutic dose)
- Week 9 onward: May remain at 0.5 mg or increase to 1 mg if additional glycemic control is needed
- After at least 4 weeks on 1 mg: May increase to 2 mg, the maximum approved dose
Wegovy (Injectable Semaglutide for Weight Management)
Wegovy is approved for chronic weight management in adults with obesity or overweight with at least one weight-related condition, and in adolescents ages 12 and older with obesity. It uses the same molecule as Ozempic but at higher target doses:
- Weeks 1–4: 0.25 mg once weekly
- Weeks 5–8: 0.5 mg once weekly
- Weeks 9–12: 1 mg once weekly
- Weeks 13–16: 1.7 mg once weekly
- Week 17 onward: 2.4 mg once weekly (maintenance)
If 2.4 mg is not tolerated, the label allows decreasing to 1.7 mg for four weeks before retrying the higher dose, with discontinuation considered if 2.4 mg still cannot be tolerated.
Rybelsus (Oral Semaglutide Tablets)
Rybelsus is the first and only oral GLP-1 receptor agonist approved for type 2 diabetes. Because semaglutide is a peptide, absorption requires an absorption enhancer (SNAC) and strict dosing conditions. It is taken in the morning on an empty stomach with no more than 4 ounces of plain water, and food, other drinks, and other oral medications should be held for at least 30 minutes afterward.
- Days 1–30: 3 mg once daily (initiation only)
- Day 31 onward: 7 mg once daily (first therapeutic dose)
- After at least 30 days at 7 mg: May increase to 14 mg daily if additional glycemic control is needed
Semaglutide Schedules Side-by-Side
| Phase | Ozempic (type 2 diabetes) | Wegovy (weight management) | Rybelsus (oral, type 2 diabetes) |
|---|---|---|---|
| Initiation | 0.25 mg weekly × 4 wk | 0.25 mg weekly × 4 wk | 3 mg daily × 30 days |
| First therapeutic step | 0.5 mg weekly | 0.5 mg weekly × 4 wk | 7 mg daily |
| Next step | 1 mg weekly (optional) | 1 mg weekly × 4 wk | 14 mg daily (optional) |
| Higher step | 2 mg weekly (max) | 1.7 mg weekly × 4 wk | Not applicable |
| Maintenance target | Varies by glycemic response | 2.4 mg weekly | 7 mg or 14 mg daily |
What Drives Schedule Adjustments
Real-world titration rarely goes by the textbook. Clinicians may hold a dose longer if nausea is limiting food intake, extend initiation for patients with a history of GERD or gastroparesis, or drop back a step if pancreatitis is suspected. Drug interactions, pregnancy planning, kidney function, and hypoglycemia risk (especially with insulin or sulfonylureas) all shape the pace. None of these adjustments should be self-directed.
Missed Doses and Restarts
Weekly semaglutide can be caught up within five days of a missed dose. Beyond that, skip and resume the schedule at the next planned injection. After long gaps of several weeks or more, many clinicians re-initiate at 0.25 mg because tolerance is lost during extended breaks. Daily Rybelsus has no catch-up; a missed dose is simply skipped.
Side Effects by Dose Phase
The most common side effects — nausea, vomiting, diarrhea, constipation, abdominal pain — are highest during the first two weeks after each dose increase and typically fade over 10–14 days. Severe or persistent vomiting should be reported, because dehydration is the leading cause of acute kidney injury on GLP-1s. Other labeled risks include pancreatitis, gallbladder disease, a boxed warning for medullary thyroid tumors, and, when combined with insulin or sulfonylureas, severe hypoglycemia.
Where Dosing Fits Into Your Prediabetes Plan
For people with prediabetes, semaglutide is not first-line therapy. The American Diabetes Association prioritizes weight loss, physical activity, and, for selected higher-risk patients, metformin. You can review foundational strategies in our treatment overview, learn how eating patterns influence glucose in our diet and nutrition hub, and check what your numbers mean at our A1C levels page.
The Bottom Line
The semaglutide dosing schedule is a tolerance-building staircase, not a prescription template you can apply on your own. Starting low, stepping up slowly, and adjusting based on how you actually feel are what separate a successful course from one that ends early because of side effects. Any dose, pace, or product change should be a conversation with a prescriber who knows your history.
